Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding, citing concerns such as immune reactions, peptide-related impurities, and limited safety information
Mouse position needs similar attention
Transcriptomic and proteomic analyses will be employed to identify genes and proteins regulated by kisspeptin-10 stimulation
Quick Facts TypePentadecapeptide (15 amino acids) CategoryRecovery / Tissue Repair AdministrationSubcutaneous injection FrequencyOnce or twice daily Typical Dose250 500 mcg/day Cycle Length4 8 weeks Available Sizes5 mg vials Stability30 days after reconstitution Overview What is BPC-157
Usually resolves within 1-2 weeks
In a phase 2 trial involving people with obesity, the 12 mg weekly dose of retatrutide resulted in a placebo-adjusted mean weight reduction of 22.1% after 48 weeks of treatment
US$ 27.76
US$ 20.75
US$ 24.21
US$ 22.26
US$ 21.56
